The AI Healthcare Divide: What Davos 2026 Missed About Global Inequality
Davos 2026 was wall-to-wall AI talk. Whether you were listening to heads of state or CEOs, the conversation kept circling back to how…
-
-
Universal Basic Income 2045: What’s Pharmacogenomics Got To Do With It?
Everyone is Googling the future of work. With fingers crossed that their current “intelligent” role—knowledge worker, analyst, developer, scientist, consultant—won’t be the next…
-
Vega, Sirius, &The Future of Pharmacogenomics
Drug prescribing is entering a new chapter. For decades, clinicians have relied on broad guidelines, trial-and-error approaches, and limited genetic information to determine…
-
OneOme to Shutdown, Deal a Blow to PGx Industry Momentum
OneOme, a leading name in pharmacogenomics testing and personalized medicine, has announced that it will cease operations by November 14, 2025, citing ongoing…
-
The Three Key Factors Driving the Rise of Preemptive Pharmacogenomics
For years, pharmacogenomics (PGx) was seen as a future promise, a fascinating science that could someday make drug therapy safer and more effective….
-
The Goldilocks Genome: Why Getting the “Just Right” Drug Could Save Lives
What if your next prescription could just as easily harm you, simply because of your genes? That unsettling question sits at the heart…
-
APGxA Interview Series: Dr. Gualberto Ruaño, M.D., Ph.D. — Physician Scientist, Innovator, and Entrepreneur
When you talk to Dr. Gualberto Ruaño, you don’t just hear about science — you hear about purpose. A physician, geneticist, and entrepreneur,…
-
The Pharmacogenomics Technology Market: Trends, Insights, and Opportunities
Grand View Research has just released its latest report on the pharmacogenomics technology market, offering fresh insights into one of the fastest-growing areas…
-
How to Navigate FDA Warnings About Unapproved Pharmacogenomic Claims
Pharmacogenetic testing has emerged as one of the most exciting frontiers in personalized medicine. By analyzing a patient’s genetic makeup, these tests promise…
-
APGxA Company Spotlight: UGenome AI
UGenome AI is a US based biotech software company developing next-generation tools for genomic data interpretation. Co-founded by CEO Zachary S. Brooks, Chief Strategy Office Peter Bannister, and Chief Genomics Officer Dr. Jayden Lee, PharmD, EMBA, the company specializes in secondary and tertiary genomic analysis—transforming raw sequencing data into actionable, repeatable insights.
End of content
End of content